Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2012 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (43)	1/3/2012 11:27:05 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 513

Fred, The prize today goes to (OSIR) with their trial results. Read the glowing comments and then suddenly right in the middle of their PR they subtly admit---their drug doesn't work. If you to read what they are saying with a keen eye note what 'difference' was seen. None! "No significant differences in the rates of disease progression, as measured by stimulated C-peptide levels at the one year time point, have been observed. However there was a trend towards fewer hypoglycemic events for patients treated with Prochymal as compared to controls."